• Twitter
  • LinkedIn
  • RSS
InterveXion Therapeutics
  • About Us
    • Overview
    • Management Team
    • Financial Conflict of Interest
  • Research & Development
    • Anti-Methamphetamine Products
    • Intellectual Property
    • Methamphetamine Use Disorder
  • Publications
    • Recent Publications
    • Anti-Methamphetamine Monoclonal Antibody
    • METH Vaccine
    • Anti-Phencyclidine Monoclonal Antibody
    • Review Articles
  • Contact Us
  • News
Select Page

InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder

Oct 4, 2021 | Anti-METH antibody, IXT-m200, General News, Grants

Grant fully funds clinical trial, to be called “OUTLAST”, which will initiate in early 2022 LITTLE ROCK, AR, USA, October 4, 2021 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the award of additional...

InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose

Oct 5, 2020 | Anti-METH antibody, IXT-m200, General News, Grants

“Meth-OD” trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical...

InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder

May 5, 2020 | Anti-METH antibody, IXT-m200, Grants

Grant fully funds manufacture of clinical supplies for Phase 2b clinical study and supports initiation of development of new subcutaneous formulation of IXT-m200 Little Rock, AR (01 May 2020) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...

InterveXion Awarded $8M to Fund Phase 2 Clinical Study of Anti-Methamphetamine Medication

Oct 10, 2017 | Anti-METH antibody, IXT-m200, General News, Grants

Little Rock, AR – InterveXion Therapeutics has received a federal grant to fund a second clinical study of IXT-m200, a monoclonal antibody designed to treat methamphetamine abuse. The clinical trial, called STAMPOUT, will be a Phase 2a, parallel-group,...

InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users

Jan 29, 2015 | Anti-METH antibody, IXT-m200, Anti-METH Vaccine, General News, Grants, Uncategorized

LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break...

NIDA Funds the First Clinical Trial of an Anti-Methamphetamine Antibody

Jul 15, 2011 | Anti-METH antibody, IXT-m200, Grants, Uncategorized

A grant to fund the First in Human, Phase 1a clinical study of anti-METH ch-mAb7F9 was awarded to UAMS and InterveXion. This three year, $3 million, award will be used to test the safety of the chimeric antibody in healthy human volunteers.
« Older Entries

Recent Posts

  • InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
  • InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
  • InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
  • InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose
  • InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder

Recent Comments

    Archives

    • October 2021
    • September 2021
    • April 2021
    • October 2020
    • May 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • May 2018
    • January 2018
    • October 2017
    • June 2017
    • January 2016
    • January 2015
    • November 2014
    • February 2014
    • August 2013
    • July 2013
    • December 2012
    • November 2012
    • May 2012
    • April 2012
    • July 2011
    • April 2011
    • October 2009
    • September 2009
    • March 2005
    • January 2005

    Categories

    • Anti-METH antibody, IXT-m200
    • Anti-METH Vaccine
    • Anti-PCP ch-mAb6B5
    • General News
    • Grants
    • METH in the news
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Twitter
    • LinkedIn
    • RSS
    © 2017 Intervexion